Research press release


Nature Medicine

Improving stroke therapy


    D Lawrenceたちは、tPAを脳内に注射すると脳の血管の透過性が高まることを明らかにした。これは、血小板由来増殖因子-CC(PDGF-CC)と呼ばれる分子が活性化されるからで、PDGF-CCを注射すると血管に対してtPAと同様の作用を示した。一方、PDGF-CCに対する抗体をtPAと同時に注射すると、血管の透過性の上昇が抑えられた。



The mechanism that may cause the undesirable bleeding associated with blood clot ‘dissolving’ enzymes is described in a paper published online this week in Nature Medicine.

    Cases of stroke caused by blood clots can be treated with tissue plasminogen activator (tPA), which ‘dissolves’ the clot but they can also lead to the nasty side effect of cerebral bleeding.

Daniel Lawrence and colleagues report that an intracerebral injection of tPA increases the permeability of cerebral blood vessels by activating a molecule known as platelet-derived growth factor-CC (PDGF-CC). Injection of PDGF-CC has an effect on blood vessels similar to that of tPA, whereas co-injection of antibodies against PDGF-CC blocks the increased permeability caused by tPA.

The authors also found that the effects of PDGF-CC depend on the activation of PDGF-alpha receptors present on brain cells lining the blood vessels. The treatment of mice with the PDGF-alpha receptor antagonist imatinib (Gleevec), which is clinically used to treat certain blood cancers, reduces vascular permeability and the hemorrhagic complications of tPA administration after stroke.

These results reveal a role for PDGF signaling in the regulation of the blood-brain barrier and identify imatinib as a potential drug to reduce the complications associated with the use of tPA in stroke.

doi: 10.1038/nm1787


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。